Selective Translation Regulator Inhibitors: Depriving cancer of what it needs

The Drug Discovery World Podcast

Вміст надано Drug Discovery World and Drug Discovery World (DDW). Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією Drug Discovery World and Drug Discovery World (DDW) або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.

1M ago 17:51

MP3•Головна епізоду

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.

In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR. eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.

Dr Worland has significant experience as a scientist and C-suite level executive/entrepreneur, and today speaks about how Selective Translation Regulator Inhibitors (STRIs) are unique to other cancer treatments, the future of the industry as well as the significance of pharma collaboration in the development process.

You can find the Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

156 епізодів

#Drugdevelopment #Drugdiscovery #Enablingtechnologies #Healthcare #Personalisedmedicine #Pharma #Biology #Informatics #Fitness #Drug Discovery World #Biopharma #Pharmacology #Science #Medicine #Business #Therapeutics #Drug Discovery World DDW #Screen